Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (RASolute 303)

I've been wanting to write about this for some time but news in UK today made all the big newspapers. I don't normally write about other cancers but I've been following this one for a while and decided to put pen to paper because it is ground-breaking.  Many people will  have heard about the new drug daraxonrasib which has taken pancreatic adenocarcinoma treatment to a new level.  The news today covered the second phase of clinical trials combining it with cytotoxic chemotherapy (in the case of this trial, GnP is a shortener of gemcitabine plus nab-paclitaxel).  When news of the…
Read More